Clinical Trials

Phase 2 Active not recruiting

Esophageal Neoplasms

NCT06670911 2025-02-24

ACCESS-I

Phase 2 Recruiting

44 enrolled

Recurrence

NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

200 enrolled

Breast

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

39 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT05910177 2024-03-06

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Phase 2 Recruiting

30 enrolled

Gynecologic

Carcinoma, Uterine Cervical Neoplasms

NCT06066216 2024-01-23

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05551767 2022-09-23

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

120 enrolled

Head and Neck Neoplasms

NCT01003964 2022-04-12

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

289 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05007145 2021-12-21

REVO

92 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04063683 2021-08-24

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

47 enrolled

Esophageal Squamous Cell Carcinoma

NCT05013697 2021-08-19

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

48 enrolled

Esophageal Neoplasms

NCT02414685 2020-08-07

TIP

19 enrolled

Neoplasms, Germ Cell and Embryonal

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

EndocrineGastrointestinalNET

112 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT01356303 2016-05-13

TAXIS01

Phase 2 Suspended

50 enrolled

Lung Neoplasms

NCT00697905 2014-11-21

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

18 enrolled

Nasopharyngeal Carcinoma

NCT01356368 2014-01-22

Customizing

Phase 2 Terminated

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00452634 2013-06-19

Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)

62 enrolled

Small Cell Lung Carcinoma

NCT00620269 2011-11-07

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

212 enrolled

Lung Neoplasms

NCT01301248 2011-05-17

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

80 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00452881 2010-10-25

Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

151 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00980603 2009-09-21

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

144 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT00886028 2009-04-22

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma